# NCT02703623 (NCT02703623)

> Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: apalutamide plus abiraterone; ipilimumab plus apalutamide plus abiraterone
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02703623
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions: Abiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin; Ipilimumab; Laboratory Biomarker Analysis; Prednisone
- Enrollment: 196
- Primary outcome: Overall survival (OS)
- Primary outcome: Incidence of adverse events as measured by the method of Thall et al
- Primary outcome: Androgen receptor (AR) response marker signature
- Primary outcome: Allocation serum marker decline

## Indexed commentary on NCT02703623 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02703623